These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053 [TBL] [Abstract][Full Text] [Related]
4. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas. Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902 [TBL] [Abstract][Full Text] [Related]
5. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin's lymphoma: a reflection of disease infiltration or just inflammation? Salaun PY; Gastinne T; Bodet-Milin C; Campion L; Cambefort P; Moreau A; Le Gouill S; Berthou C; Moreau P; Kraeber-Bodéré F Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1813-21. PubMed ID: 19499219 [TBL] [Abstract][Full Text] [Related]
6. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma. Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value of baseline and interim [ Yadgarov MY; Dunaykin MM; Shestopalov GI; Kailash C; Kireeva ED; Myakova NV; Likar YN Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1955-1964. PubMed ID: 38351389 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study. Zwarthoed C; El-Galaly TC; Canepari M; Ouvrier MJ; Viotti J; Ettaiche M; Viviani S; Rigacci L; Trentin L; Rusconi C; Luminari S; Cantonetti M; Bolis S; Borra A; Darcourt J; Salvi F; Subocz E; Tajer J; Kulikowski W; Malkowski B; Zaucha JM; Gallamini A J Nucl Med; 2017 Aug; 58(8):1249-1254. PubMed ID: 28126883 [TBL] [Abstract][Full Text] [Related]
9. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of imaging markers from 18FDG-PET/CT in paediatric patients with Hodgkin lymphoma. Rodríguez Taroco MG; Cuña EG; Pages C; Schelotto M; González-Sprinberg GA; Castillo LA; Alonso O Nucl Med Commun; 2021 Mar; 42(3):306-314. PubMed ID: 33306628 [TBL] [Abstract][Full Text] [Related]
11. Variety in bone marrow 18F-FDG uptake in Hodgkin lymphoma patients without lymphomatous bone marrow involvement: does it have an explanation? Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC Nucl Med Commun; 2016 Jan; 37(1):23-9. PubMed ID: 26440567 [TBL] [Abstract][Full Text] [Related]
12. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment]. Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636 [No Abstract] [Full Text] [Related]
13. Optimisation of metabolic criteria in the prognostic assessment in patients with lymphoma. A multicentre study. Del Puig Cózar-Santiago M; García-Garzón JR; Moragas-Freixa M; Soler-Peter M; Bassa Massanas P; Sánchez-Delgado M; Sanchez-Jurado R; Aguilar-Barrios JE; Sanz-Llorens R; Ferrer-Rebolleda J Rev Esp Med Nucl Imagen Mol; 2017; 36(5):304-311. PubMed ID: 28483373 [TBL] [Abstract][Full Text] [Related]
14. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients. Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003 [TBL] [Abstract][Full Text] [Related]
15. Utility of Jitani AK; Dutta S; Mandal PK; De R; Jajodia E; Baul S; Chakrabarti P; Dolai TK Indian J Med Res; 2021 May; 154(5):691-698. PubMed ID: 35532587 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria. Min M; Lin P; Lee M; Ho Shon I; Lin M; Forstner D; Tieu MT; Chicco A; Bray V; Fowler A Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):393-401. PubMed ID: 26782837 [TBL] [Abstract][Full Text] [Related]
17. Combined prognostic role of TARC and interim Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858 [TBL] [Abstract][Full Text] [Related]
18. The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma. Subesinghe M; Ilyas H; Dunn JT; Mir N; Duran A; Mikhaeel NG; Barrington SF Clin Radiol; 2023 Feb; 78(2):e89-e98. PubMed ID: 36333130 [TBL] [Abstract][Full Text] [Related]
19. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Moulin-Romsee G; Hindié E; Cuenca X; Brice P; Decaudin D; Bénamor M; Brière J; Anitei M; Filmont JE; Sibon D; de Kerviler E; Moretti JL Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1095-105. PubMed ID: 20204358 [TBL] [Abstract][Full Text] [Related]
20. PET/CT: Clinical role in lymphomas. Papathanasiou N Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560 [No Abstract] [Full Text] [Related] [Next] [New Search]